Why Nobel Laureates See Artificial Intelligence as the Future of Scientific Discovery
Guangzhou, Wednesday, 23 September 2026.
Nobel laureates highlight how artificial intelligence and gene-silencing technologies are transforming research speed and medical treatments, bridging the gap between computational discovery and physical validation.
AI and Experimental Validation in Structural Biology
On September 23, 2026, Southern Finance Media Corp and 21st Century Business Herald released interviews with Nobel laureates regarding scientific innovation [1]. Joachim Frank, the 2017 Nobel Prize laureate in Chemistry, emphasized that while AI accelerates data processing, experimental work remains essential for validating new evidence [1]. Frank noted that AI systems rely on existing knowledge, whereas scientific research requires observations to test new hypotheses [1]. His research history illustrates the synergy between computational and experimental methods, specifically in cryo-electron microscopy [1]. This technique reconstructs three-dimensional molecular structures from noisy, two-dimensional electron microscopy images [1]. Frank stated that experimental work remains an important means of testing hypotheses and investigating phenomena that are not yet understood [1].
Computational Tools and Research Barriers
Michael Levitt, the 2013 Nobel Prize laureate in Chemistry, described AI as a powerful tool for processing large volumes of scientific literature [3]. Levitt stated that AI has not yet demonstrated the ability to conduct scientific research independently but supports researchers in exploring new areas [3]. He suggested that AI could lower barriers to entering new scientific fields and accelerate the pace of exploration [3]. According to Levitt, as information can be processed and shared more rapidly, AI may contribute to the continued global exchange of scientific knowledge [3]. He noted that the development of AI represents a significant technological change that could influence how scientific work is conducted [3]. The interview highlighted that scientific knowledge has historically moved across borders while major centers of research shift over time [3].
RNA Interference and Medical Applications
Craig C. Mello, the 2006 Nobel Prize laureate in Physiology or Medicine, discussed RNA interference and its application in biomedical research [2]. Mello highlighted that RNAi is a fundamental mechanism cells use to regulate gene expression and defend against viral infections [2]. Current investigations are targeting cardiovascular diseases and rare diseases using these RNA-based treatments [2]. Research into RNA interference has transitioned from fundamental molecular biology to clinical applications [2]. Mello stated that the development of these technologies reflects the growing ability of researchers to move from understanding biological mechanisms toward developing ways to intervene in them [2]. He was awarded the Nobel Prize in Physiology or Medicine in 2006 for the discovery of RNA interference [2].
Commercial Shifts in Biotechnology
The interviews signal major commercial and technological shifts across the global biotechnology sector [1][2][3]. The series, titled “High-Level Interviews: Conversations with Global Scientific Giants,” focuses on advancements in science and technology [1][2][3]. These insights bridge the gap between expert discourse and layman’s understanding of current financial and economic events in science [1][2][3]. The content is distributed by Dongfang Yiyang (Beijing) Consulting Co., Ltd., indicating international interest in these scientific developments [1]. The discussions underscore that while AI accelerates parts of the research process, physical validation remains critical [1]. Collectively, the laureates outline how artificial intelligence and RNA interference are fundamentally transforming experimental science and medicine [1][2][3].